您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Talquetamab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Talquetamab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:2226212-40-2
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议
100mg电议

产品名称
JNJ-64407564
产品介绍
Talquetamab(JNJ-64407564)是一种人源化的双特异性抗体,可与GPRC5D(G 蛋白偶联受体家族C5组成员 D) 和CD3结合,通过T 细胞的募集和活化诱导 T 细胞介导的杀死表达 GPRC5 的 MM 细胞。Talquetamab(JNJ-64407564)具有抗肿瘤活性。
生物活性

Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds toGPRC5D(member of G protein-coupled receptor family C5 group D) andCD3to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity[1][2].

体外研究
(In Vitro)

Talquetamab (0.00128-4.0 μg/mL, 48 h) 有效诱导多发性骨髓瘤细胞裂解,并导致活化的 CD4+和CD8+T 细胞比例显著增加,以及颗粒酶 B 和炎症细胞因子如 IL-6、IL-8 和 TNF-α 水平的剂量依赖性增加[1].

体内研究
(In Vivo)

Talquetamab (JNJ-64407564) (0.1-50 μg, s.c. or i.v.)在 H929 和 MM 小鼠模型中有明显的抗肿瘤活性[2]

Animal Model:Female NSG mice with H929 cells[2]
Dosage:0.1-10 μg (0.005 mg/kg)
Administration:Subcutaneous injection; on days 0, 3, 5, 7, and 10
Result:Completely blocked tumor formation at 1 μg and 10 μg doses.
Animal Model:Female NSG mice with human MM cells[2]
Dosage:0.1-50 μg (0.005 mg/kg)
Administration:Intravenous injection; on days 15, 18, 22, 24, 29, 32, and 36
Result:Significantly inhibited tumor growth by 65% at the dose of 1μg and showed significant anti-tumor activity at 10 and 50 μg with complete tumor regression.
性状

Liquid

CAS 号

2226212-40-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.